The data shows that downregulating PU.1 promotes the expression of immunoregulatory proteins on microglia that help protect cognitive function.

A novel 3D-printed nanofiltration module delivers nearly double the saccharide recovery rate and lowers costs.

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

The goal of the project is to develop novel approaches that strengthen and reduce the costs of domestic mAb biomanufacturing to protect against and treat infection by filoviruses.

Small biotechs are encouraged to develop robust processes early to avoid wasted time and increased costs on repeating scale-up.

More analysis is needed to help manufacturers stop protein therapeutics from sticking to surfaces during downstream production operations.

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.

CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation.